Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
- Author:
Sun Min LIM
1
;
Sang Hee CHO
;
In Gyu HWANG
;
Jae Woo CHOI
;
Hyun CHANG
;
Myung Ju AHN
;
Keon Uk PARK
;
Ji Won KIM
;
Yoon Ho KO
;
Hee Kyung AHN
;
Byoung Chul CHO
;
Byung Ho NAM
;
Sang Hoon CHUN
;
Ji Hyung HONG
;
Jung Hye KWON
;
Jong Gwon CHOI
;
Eun Joo KANG
;
Tak YUN
;
Keun Wook LEE
;
Joo Hang KIM
;
Jin Soo KIM
;
Hyun Woo LEE
;
Min Kyoung KIM
;
Dongmin JUNG
;
Ji Eun KIM
;
Bhumsuk KEAM
;
Hwan Jung YUN
;
Sangwoo KIM
;
Hye Ryun KIM
Author Information
- Publication Type:Clinical Trial ; Original Article
- Keywords: Squamous cell carcinoma of the head and neck; Next-generation sequencing; Molecular Targeted Therapy; Biomarkers; Clinical trial
- MeSH: Biomarkers; Carcinoma, Squamous Cell*; Cisplatin; Epithelial Cells*; Head*; Humans; Korea; Molecular Targeted Therapy; Neck*; Precision Medicine; Statistics as Topic
- From:Cancer Research and Treatment 2019;51(1):300-312
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients. MATERIALS AND METHODS: Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data. RESULTS: Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%). CONCLUSION: We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.
